Most Read Articles
Pearl Toh, Yesterday
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 4 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Oesophageal radiofrequency fails to deliver in PPI-refractory heartburn

02 Aug 2020

In heartburn patients who do not respond to proton pump inhibitor (PPI) treatment, the oesophageal radiofrequency procedure falls short of relieving symptoms and reducing PPI use, a study has shown.

Sixty-two patients (mean age, 51.2 years) were randomized to undergo radiofrequency (n=29) or a sham procedure (n=33). All patients had moderate‐to‐severe heartburn, defined by at least three events a week and not improved by continuous PPI treatment (single dose, n=15; double dose, n=47).

According to 24-hour pH-impedance monitoring on PPIs, 29 patients had functional heartburn, 17 reflux hypersensitivity, 10 persisting gastroesophageal reflux disease, and six were not classified (normal reflux parameters but no symptoms recorded).

The oesophageal radiofrequency procedure was performed under general anaesthesia after endotracheal intubation. A flexible radiofrequency catheter was introduced, and four needle electrodes were deployed into the muscular layer of the oesophageal wall to deliver the energy. The sham procedure followed the same protocols but without delivering the energy.

Intention‐to‐treat analysis showed that more patients in the sham group than in the active treatment group achieved the primary endpoint of clinical success at week 24 (5 vs 1), although the difference was not significant. Success was defined by intake of fewer than seven PPI doses over the 2 preceding weeks and adequate symptom control, as determined by the patient.

Oesophageal radiofrequency neither reduced the number of days without heartburn and days on PPI in the previous 2 weeks nor increased the number of patients discontinuing PPI compared with sham.

No pH‐impedance parameter predicted clinical response, and the occurrence of adverse events was similar in both groups.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 4 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.